ZINACEF INJECTION - PWS IM IV 750MG/VIAL DIN 02213532
Health Canada record
| Active ingredient(s) | CEFUROXIME SODIUM 750 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous; Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01DC02 CEFUROXIME |
| Original market date | 20-Aug-2001 |
| Current status date | 30-Nov-2007 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEFUROXIME SODIUM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01940252 | KEFUROX INJ PWS 1.5GM/ADD-VANTAGE VIAL | ELI LILLY CANADA INC | Powder For Solution | CEFUROXIME SODIUM 1.5 G | Cancelled Post Market |
| 02213540 | ZINACEF INJECTION - PWS IV 1.5GM/VIAL | GLAXOSMITHKLINE INC | Powder For Solution | CEFUROXIME SODIUM 1.5 G | Cancelled Post Market |
| 02213559 | ZINACEF INJECTION - PWS IV 7.5GM/VIAL | GLAXOSMITHKLINE INC | Powder For Solution | CEFUROXIME SODIUM 7.5 G | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 364 | 2002-05-08 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 4306 | 1996-03-12 | New Drug Submission (NDS) |
International API supply for CEFUROXIME SODIUM
6 active FDA Drug Master Files.
Request a quote for ZINACEF INJECTION - PWS IM IV 750MG/VIAL